View More
Rapid ART initiation at CrescentCare Health Clinic within 72 hrs of diagnosis and prior to obtaining laboratory results was effective and well tolerated in adults and young persons (18-24 yrs) with HIV.
Higher rates of virologic suppression at delivery and fewer adverse birth outcomes in treatment-naive women initiating DTG-based ART vs EFV/FTC/TDF during pregnancy.
Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.
Long-term pooled analysis of Studies 1489 and 1490 demonstrated comparable efficacy and safety, including renal and bone outcomes, in older and younger patients initiating BIC/FTC/TAF vs DTG-based 3-drug regimens.
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.
Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.
Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.
Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.
Post hoc analysis found that patients initiating EFV-based ART who were categorized by CYP2B6 genotyping as slow metabolizers had less weight gain compared with extensive metabolizers and those initiating DTG-based ART.
Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.
USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602
(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.